Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company's website at www.eledon.com.
Research and Financial Data on Eledon Pharmaceuticals
Please complete the form below to submit your registration request for Eledon Pharmaceuticals Virtual One-on-One Meeting, to be held September 23, 2024 via Zoom, presented by Noble Capital Markets. This meeting is open to qualified investors, and offered at no cost.
A representative will contact you, using the information you provide below, with more details on attending the event.
© 2023 Noble Capital Markets, Inc.
Noble Capital Markets, Inc. Members FINRA, SIPC, MSRB